Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: Niemann Pick Disease

April 21, 2023 CD as API / Pharma applications

The review article ‘Molecular Mind Games’ describes the latest developments in cyclodextrin research for the treatment of brain disorders

The human brain is a complex and intricate network of cells and molecules that control every aspect of our behaviour

Continue reading

April 14, 2023 CD as API / CD derivatives / Pharma applications

Grafting of Cyclodextrin to Theranostic Nanoparticles Improves Blood-Brain Barrier Model Crossing

Core–shell superparamagnetic iron oxide nanoparticles hold great promise as a theranostic platform in biological systems. Herein, we report the biological

Continue reading

December 1, 2022 CD as API / Pharma applications

Cyclodextrins: Only Pharmaceutical Excipients or Full-Fledged Drug Candidates?

In this review, based on 250 references, the general chemical principles of direct cyclodextrin–protein interactions are summarized and highlighted, through

Continue reading

October 11, 2022 CD as API / Pharma applications

Inclusion Solves Insolubility ―Translational Research Cycle from Bedside to Bench and Bench to Bedside for Drug Development Targeting Niemann-Pick Disease Type C

Cyclodextrins (CDs) are used not only as pharmaceutical excipients but also as active pharmaceutical ingredients. CDs can act as artificial

Continue reading

October 5, 2022 CD as API / CD derivatives

Monosubstituted Maltosyl Cyclodextrins for the Potential Treatment of NPC

Niemann-Pick type C is a sever lysosomal storage disease, commonly refereed as ‘children’s Alzheimer’. There is no cure for it

Continue reading

August 3, 2022 CD as API / Pharma applications

HPaCD against Alzheimer Disease

HP-beta-cyclodextrin (HPbCD) is currently in clinical trials against Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease (AD) and these trials

Continue reading

July 12, 2022 CD as API / Events / Pharma applications

Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation

Presentation by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol® Cyclo™ Program Steering Committee and the Global Principal Investigator

Continue reading

June 1, 2022 CD as API / Pharma applications

Brain uptake and distribution patterns of 2-hydroxypropyl-ß-cyclodextrin after intrathecal and intranasal administration

2-hydroxypropyl-ß-cyclodextrin (kleptose) is used for the treatment of Niemann–Pick disease. Kleptose crosses the blood–brain barrier poorly, in part because of

Continue reading

May 12, 2022 CD as API / Pharma applications

Cothreading of Unmodified and Monoazidated β-Mixed cyclodextrins in polyrotaxanes for Niemann Pick disease

To establish a method for the orthogonal chemical functionalization of β-cyclodextrin (β-CD)-based polyrotaxane (PRX), unmodified and monoazidated β-CDs (N3-β-CDs) were

Continue reading

March 14, 2022 CD as API / Pharma applications

Cyclo Therapeutics on Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C

Businesswire published: Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase

Continue reading

Posts navigation

1 2 3 … 5 Next Posts»

Recent Posts

  • Pharmacokinetic studies of hyperoside-2-hydroxypropyl-β-cyclodextrin inclusion complex and ameliorated colitis in mice
  • A review on Sulfobutylether-β-cyclodextrin for drug delivery applications
  • Green materials with promising applications: Cyclodextrins-based deep eutectic supramolecular polymers
  • Antifungal pentachloronitrobenzene/hydroxypropyl-beta-cyclodextrin inclusion complex nanofibers by electrospinning with no polymer
  • Special issue of EuroCD2023 is open for submission

Tags

alpha-CD Alzheimer disease Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems FDA Food Gilead HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Sugammadex Synthesis wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (15)
  • Analysis (37)
  • CD as API (214)
  • CD derivatives (269)
  • Cosmetics and toilettry (22)
  • Diagnosis (1)
  • Drug delivery (460)
  • E-ducation (56)
  • Environmental (80)
  • Events (163)
  • Food (128)
  • Gene delivery (10)
  • In Hungarian (4)
  • Life sciences (19)
  • Non-pharma applications (228)
  • Other industrial use (69)
  • Pharma applications (729)
  • Supramolecular systems (27)
  • Uncategorized (47)

Top Posts

  • Pharmacokinetic studies of hyperoside-2-hydroxypropyl-β-cyclodextrin inclusion complex and ameliorated colitis in mice
  • Lanosterol eye drops for cataract treatment
  • A review on Sulfobutylether-β-cyclodextrin for drug delivery applications
  • Special issue of EuroCD2023 is open for submission
  • Antifungal pentachloronitrobenzene/hydroxypropyl-beta-cyclodextrin inclusion complex nanofibers by electrospinning with no polymer
  • Green materials with promising applications: Cyclodextrins-based deep eutectic supramolecular polymers
  • 7th European Cyclodextrin Conference
  • International Symposium of Drug Delivery Systems (SDDS-2022)
  • Breathtaking anatomical view of a mammalian organism enabled by DIMEB
  • Recent books on cyclodextrins

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 552 other subscribers
 

Loading Comments...